AI Visibility Scorecard
ENTYVIO® (vedolizumab) for Crohn's Disease or Ulcerative Colitis
entyvio.com · Healthcare
Somewhat visible. AI bots can read ENTYVIO® (vedolizumab) for Crohn's Disease or Ulcerative Colitis, but it is missing the structured signals that push citation rate above competitors.
AI engines read this profile 8 times
Claude · Apple Intelligence · Meta AI · ShapBot
#138,143 of 923,684 in Healthcare for AI visibility
6
AEO Visibility
iBorderline · 5.6/10
50
Muse Index Score
iAI agent readiness
Agent-ready · 50/100
0
AI Adoption
iNone detected · 0/100
About ENTYVIO® (vedolizumab) for Crohn's Disease or Ulcerative Colitis
from our crawl and measurement
ENTYVIO, based in Cambridge, MA, describes itself simply: "ENTYVIO is a biologic treatment for moderate to severe Crohn's disease (CD) or ulcerative colitis (UC). See Safety and Prescribing Information." To AI engines like ChatGPT and Perplexity it is partially visible, scoring 5.6 out of 10, readable in places and missing in others.
Our crawl found structured data on the page (MedicalWebPage), a sitemap and a readable heading structure. It is missing an llms.txt file.
AI crawlers have visited once in our tracking, including ClaudeBot (Anthropic).
The 6 signals AI reads
Strong · Good · Fair · Weak
Structured Data
Weak
Organization / LocalBusiness JSON-LD that AI can read.
Content Structure
Strong
Clear headings and answer-style content.
Entity Clarity
Strong
How clearly your brand identity reads to AI.
E-E-A-T Signals
Experience, Expertise, Authority, Trust
Weak
Experience, Expertise, Authority, Trust markers.
Technical AEO
Good
robots.txt, llms.txt, and AI-bot crawl access.
AI Discoverability
Good
Sitemaps and entity links AI can follow.
Off-page authority
How the web signals your brand to AI
Backlinks
Strong
Inbound links from other sites.
Domain Authority
Weak
Little domain authority yet.
Reference Presence
Weak
Not in AI knowledge graphs yet.
News & Press
Weak
No press coverage found yet.
Community
Weak
No community discussion yet.
Social Mentions
Weak
No social discussion found yet.
What this score means
Your AEO score measures whether AI search engines - ChatGPT, Claude, Perplexity, Gemini - can actually read your site and cite it in answers. Roughly two-thirds of sites are invisible to them. At 5.6/10, ENTYVIO® (vedolizumab) for Crohn's Disease or Ulcerative Colitis has a working base to build on - fixable, and the signals above are where to start.
Frequently Asked Questions
What is ENTYVIO?
ENTYVIO (vedolizumab) is a biologic used to treat Crohn’s disease and ulcerative colitis when certain other medicines haven’t worked well enough or could not be tolerated. Doctors have prescribed ENTYVIO for over 10 years. With ENTYVIO, there are options ENTYVIO can be administered 2 different ways, by IV infusion or by a self-administered injection, also known as the ENTYVIO Pen.
Is this your brand?
The exact fixes for ENTYVIO® (vedolizumab) for Crohn's Disease or Ulcerative Colitis
Which AI engines already crawl you
Free AI bot monitoring: see every AI crawler that visits you
How to Get Your Brand Cited by ChatGPT, Gemini, and Claude: The Complete AEO Guide
The search landscape has fundamentally shifted. While Google still dominates, millions of users now ask questions to ChatGPT, Gemini, and Claude instead of typing into a search bar.
Continue reading in your free Engagemii portalFree signup unlocks the full article plus your personalized AEO fix list for ENTYVIO® (vedolizumab) for Crohn's Disease or Ulcerative Colitis.
Source & Attribution
Scored by Engagemii on August 7, 2026. Methodology: engagemii.com/aeo/methodology
Source URL: https://engagemii.com/aeo/brands/entyvio
Cite this score: Engagemii (2026). "AEO Score for ENTYVIO® (vedolizumab) for Crohn's Disease or Ulcerative Colitis." Retrieved from https://engagemii.com/aeo/brands/entyvio
Licensed under CC BY 4.0. You may reuse this data with attribution: a visible link to engagemii.com.
Powered by Engagemii - The Answer Engine Optimization (AEO) Platform